This biotechnology company develops first-in-class targeted biotherapeutics, called AIM biologicals, for the treatment of autoimmune diseases. These therapies leverage a physiological tolerance mechanism to offer a novel approach to managing autoimmune conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for autoimmune diseases often rely on broad immunosuppression, which can lead to significant side effects, including increased risk of opportunistic infections. These therapies lack the specificity needed to target only the pathogenic immune responses, while preserving overall immune function. This creates a need for more precise and targeted therapeutic approaches.
Solution
Toleris Biotherapeutics is developing AutoImmunity Modifying Biologicals (AIM Bios), a platform of soluble proteins designed to induce selective, antigen-specific immunological tolerance in targeted organs. AIM Bios leverage a natural mechanism inspired by pregnancy, where the maternal immune system tolerates fetal antigens. By mimicking this process, AIM Bios aim to selectively tolerize the immune system to autoantigens, addressing the root cause of autoimmune diseases without broadly suppressing the immune system. This targeted approach has the potential to halt disease progression while minimizing the risk of opportunistic infections.
Target Audience
The primary target audience includes individuals suffering from autoimmune diseases such as multiple sclerosis (MS), MOG antibody disease (MOGAD), neuromyelitis optica spectrum disorders (NMOSD), Parkinson's disease, and type 1 diabetes.
Features
- Soluble, near-physiological proteins that induce antigen-specific immunological tolerance.
- Mimic the natural mechanism of immune tolerance observed during pregnancy.
- Designed to selectively target pathogenic immune responses while preserving overall immune function.
- Induce regulatory CD8+ T cells (Tregs) that migrate to affected tissues and promote local immunosuppression and tissue regeneration.
- Can be adapted to various autoimmune diseases by modifying the antigen-binding domains.
- Demonstrated preclinical efficacy in mouse models of multiple sclerosis (MS) and other autoimmune diseases.
- GMP manufacturing process planned for AIM Bios to ensure high purity and stability.